Disease-modifying anti-rheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study.

Naohisa MiyakawaKatsuki TsuritaniBruno Casaes TeixeiraKeishi Fujio

Published in: Modern rheumatology (2024)

Methotrexate is used less frequently among older Japanese RA patients or those with comorbidities. Abatacept is the most frequently used drug, followed by IL-6Ri, in patients not using methotrexate at the treatment start.

Keyphrases

end stage renal disease
newly diagnosed
rheumatoid arthritis
ejection fraction
chronic kidney disease
high dose
prognostic factors
emergency department
low dose
patient reported outcomes
systemic lupus erythematosus
adverse drug
ankylosing spondylitis
drug induced